The study tested two doses of Abrysvo in 203 adults across four groups - those with a type of lung cancer, end-stage kidney disease, autoimmune inflammatory disorder, and solid organ transplant recipients - all of whom have compromised immunity and are at risk of developing severe RSV-associated disease.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/YFVjST9
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment